OBJECTIVES: To estimate nevirapine (NVP) pharmacokinetics and examine its association with rashand/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa. DESIGN: In HIV-infected, nonpregnant women with screening CD4 cell count less than 200 cells/μl randomized toNVP (twice daily, after 14-day once-daily lead-in period) and tenofovir/emtricitabine, single NVP blood samples were collected 14 and 28 days following randomization. Rash and hepatotoxicity that occurred during therapy, or within 7 days after the last dose of NVP, were defined as toxicity. METHODS:NVP pharmacokinetics were modeled by population pharmacokinetic analysis. Individual Bayesian pharmacokinetic estimates were used to calculate clearance, 24-h area under the curve, and predicted plasma concentrations. RESULTS: Median week 4 NVP clearance was 2 l/h. Among the 359 women, 194 (54%) developed a rash of any grade; 82 (23%) had grade 2+ and nine (3%) had grade 3+ rash. Median clearance was 1.7 l/h for participants exhibiting 3+ rash versus 2 l/h in women without 3+ rash (P = 0.046). The odds of developing 3+ rash was 50% higher for every 20% decrease in clearance (P = 0.046). NVP discontinuation due to rash/liver toxicity was significantly more common among women with pretreatment CD4 cell count more than 250 cells/μl (P = 0.003). CONCLUSION: In this study, HIV-infected African women starting aNVP-based antiretroviral regimen had a lower NVP clearance compared to previous reports. Severe rash, but not hepatotoxicity, was associated with higher NVP exposure. Albeit observed in a small number of women, baseline CD4 cell count at least 250 cells/μl was significantly associated with NVP toxicity.
RCT Entities:
OBJECTIVES: To estimate nevirapine (NVP) pharmacokinetics and examine its association with rash and/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa. DESIGN: In HIV-infected, nonpregnant women with screening CD4 cell count less than 200 cells/μl randomized to NVP (twice daily, after 14-day once-daily lead-in period) and tenofovir/emtricitabine, single NVP blood samples were collected 14 and 28 days following randomization. Rash and hepatotoxicity that occurred during therapy, or within 7 days after the last dose of NVP, were defined as toxicity. METHODS:NVP pharmacokinetics were modeled by population pharmacokinetic analysis. Individual Bayesian pharmacokinetic estimates were used to calculate clearance, 24-h area under the curve, and predicted plasma concentrations. RESULTS: Median week 4 NVP clearance was 2 l/h. Among the 359 women, 194 (54%) developed a rash of any grade; 82 (23%) had grade 2+ and nine (3%) had grade 3+ rash. Median clearance was 1.7 l/h for participants exhibiting 3+ rash versus 2 l/h in women without 3+ rash (P = 0.046). The odds of developing 3+ rash was 50% higher for every 20% decrease in clearance (P = 0.046). NVP discontinuation due to rash/liver toxicity was significantly more common among women with pretreatment CD4 cell count more than 250 cells/μl (P = 0.003). CONCLUSION: In this study, HIV-infected African women starting a NVP-based antiretroviral regimen had a lower NVP clearance compared to previous reports. Severe rash, but not hepatotoxicity, was associated with higher NVP exposure. Albeit observed in a small number of women, baseline CD4 cell count at least 250 cells/μl was significantly associated with NVPtoxicity.
Authors: Mario Regazzi; Paola Villani; Elena Seminari; Giovanni Ravasi; Maria Cusato; Francesca Marubbi; Grazia Meneghetti; Renato Maserati Journal: AIDS Date: 2003-11-07 Impact factor: 4.177
Authors: Monique M R de Maat; Jeannine F J B Nellen; Alwin D R Huitema; Ferdinand W M N Wit; Jan W Mulder; Jan M Prins; Jos H Beijnen Journal: Ther Drug Monit Date: 2004-08 Impact factor: 3.681
Authors: F van Leth; P Phanuphak; K Ruxrungtham; E Baraldi; S Miller; B Gazzard; P Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; R Wood; G C Levi; G Reboredo; K Squires; I Cassetti; D Petit; F Raffi; C Katlama; R L Murphy; A Horban; J P Dam; E Hassink; R van Leeuwen; P Robinson; F W Wit; J M A Lange Journal: Lancet Date: 2004-04-17 Impact factor: 79.321
Authors: Monique M R de Maat; Rob ter Heine; Jan W Mulder; Pieter L Meenhorst; Albert T A Mairuhu; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen Journal: Eur J Clin Pharmacol Date: 2003-08-12 Impact factor: 2.953
Authors: Eric Dailly; Eric Billaud; Véronique Reliquet; Sébastien Breurec; Philippe Perré; Sophie Léautez; Pascale Jolliet; Michel Bourin; François Raffi Journal: Eur J Clin Pharmacol Date: 2004-05-20 Impact factor: 2.953
Authors: Courtney V Fletcher; Hongyu Jiang; Richard C Brundage; Edward P Acosta; Richard Haubrich; David Katzenstein; Roy M Gulick Journal: J Infect Dis Date: 2004-03-16 Impact factor: 5.226
Authors: Cynthia Firnhaber; Laura M Smeaton; Beatriz Grinsztejn; Umesh Lalloo; Sharla Faesen; Wadzanai Samaneka; Rosa Infante; Aadia Rana; Nagalingeswaran Kumarasamy; James Hakim; Thomas B Campbell Journal: HIV Clin Trials Date: 2015-05-15
Authors: Andrzej Bienczak; Paolo Denti; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Diana M Gibb; David Burger; Ann S Walker; Helen McIlleron Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: E H Decloedt; J Mwansa-Kambafwile; J-S van der Walt; H McIlleron; P Denti; P Smith; L Wiesner; M Rangaka; R J Wilkinson; G Maartens Journal: Int J Tuberc Lung Dis Date: 2013-03 Impact factor: 2.373
Authors: Julie Bertrand; Monidarin Chou; Danielle M Richardson; Céline Verstuyft; Paul D Leger; France Mentré; Anne-Marie Taburet; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089
Authors: Lianxing Liu; Lin Wang; Liusheng Huang; Vincent Siu; Fernando Teque; Francesca T Aweeka; Jay A Levy Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731